|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rodríguez Villalba S1, Díaz-Caneja Planell
C and Cervera Grau JM: Current opinion in cervix carcinoma. Clin
Transl Oncol. 13:378–384. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roy DM and Walsh LA: Candidate prognostic
markers in breast cancer: Focus on extracellular proteases and
their inhibitors. Breast Cancer. 6:81–91. 2014.PubMed/NCBI
|
|
4
|
Netzel-Arnett S, Hooper JD, Szabo R,
Madison EL, Quigley JP, Bugge TH and Antalis TM: Membrane anchored
serine proteases: A rapidly expanding group of cell surface
proteolytic enzymes with potential roles in cancer. Cancer
Metastasis Rev. 22:237–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bugge TH, Antalis TM and Wu Q: Type II
transmembrane serine proteases. J Biol Chem. 284:23177–23181. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hooper JD, Clements JA, Quigley JP and
Antalis TM: Type II transmembrane serine proteases. Insights into
an emerging class of cell surface proteolytic enzymes. J Biol Chem.
276:857–860. 2001. View Article : Google Scholar
|
|
7
|
Scott HS, Kudoh J, Wattenhofer M, Shibuya
K, Berry A, Chrast R, Guipponi M, Wang J, Kawasaki K, Asakawa S, et
al: Insertion of beta-satellite repeats identifies a transmembrane
protease causing both congenital and childhood onset autosomal
recessive deafness. Nat Genet. 27:59–63. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wallrapp C, Hähnel S, Müller-Pillasch F,
Burghardt B, Iwamura T, Ruthenbürger M, Lerch MM, Adler G and Gress
TM: A novel transmembrane serine protease (TMPRSS3) overexpressed
in pancreatic cancer. Cancer Res. 60:2602–2606. 2000.PubMed/NCBI
|
|
9
|
Iacobuzio-Donahue CA, Ashfaq R, Maitra A,
Adsay NV, Shen-Ong GL, Berg K, Hollingsworth MA, Cameron JL, Yeo
CJ, Kern SE, et al: Highly expressed genes in pancreatic ductal
adenocarcinomas: A comprehensive characterization and comparison of
the transcription profiles obtained from three major technologies.
Cancer Res. 63:8614–8622. 2003.PubMed/NCBI
|
|
10
|
Al Saleh S, Sharaf LH and Luqmani YA:
Signalling pathways involved in endocrine resistance in breast
cancer and associations with epithelial to mesenchymal transition
(Review). Int J Oncol. 38:1197–1217. 2011.PubMed/NCBI
|
|
11
|
Reddy KB, Nabha SM and Atanaskova N: Role
of MAP kinase in tumor progression and invasion. Cancer Metastasis
Rev. 22:395–403. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kebebew E, Peng M, Reiff E, Duh QY, Clark
OH and McMillan A: ECM1 and TMPRSS4 are diagnostic markers of
malignant thyroid neoplasms and improve the accuracy of fine needle
aspiration biopsy. Ann Surg. 242:353–361. 2005.PubMed/NCBI
|
|
13
|
Liang B, Wu M, Bu Y, Zhao A and Xie F:
Prognostic value of TMPRSS4 expression in patients with breast
cancer. Med Oncol. 30:4972013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guerrero K, Wang Z, Bachvarova M, Gregoire
J, Renaud MC, Plante M and Bachvarov D: A novel genome-based
approach correlates TMPRSS3 overexpression in ovarian cancer with
DNA hypomethylation. Gynecol Oncol. 125:720–726. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang J, Guo H, Mi Z, Gao C, Bhattacharya
S, Li J and Kuo PC: EF1A1-actin interactions alter mRNA stability
to determine differential osteopontin expression in HepG2 and Hep3B
cells. Exp Cell Res. 315:304–312. 2009. View Article : Google Scholar
|
|
16
|
Guan H, Liang W, Liu J, Wei G, Li H, Xiu
L, Xiao H and Li Y: Transmembrane protease serine 4 promotes
thyroid cancer proliferation via CREB phosphorylation. Thyroid.
25:85–94. 2015. View Article : Google Scholar
|
|
17
|
Larzabal L, Nguewa PA, Pio R, Blanco D,
Sanchez B, Rodríguez MJ, Pajares MJ, Catena R, Montuenga LM and
Calvo A: Overexpression of TMPRSS4 in non-small cell lung cancer is
associated with poor prognosis in patients with squamous histology.
Br J Cancer. 105:1608–1614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim S, Kang HY, Nam EH, Choi MS, Zhao XF,
Hong CS, Lee JW, Lee JH and Park YK: TMPRSS4 induces invasion and
epithelial-mesenchymal transition through upregulation of integrin
alpha5 and its signaling pathways. Carcinogenesis. 31:597–606.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li T, Zeng ZC, Wang L, Qiu SJ, Zhou JW,
Zhi XT, Yu HH and Tang ZY: Radiation enhances long-term metastasis
potential of residual hepatocellular carcinoma in nude mice through
TMPRSS4-induced epithelial-mesenchymal transition. Cancer Gene
Ther. 18:617–626. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leshem O, Madar S, Kogan-Sakin I, Kamer I,
Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M,
Ben-Sasson S, et al: TMPRSS2/ERG promotes epithelial to mesenchymal
transition through the ZEB1/ZEB2 axis in a prostate cancer model.
PLoS One. 6:e216502011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khan MA, Chen HC, Zhang D and Fu J: Twist:
A molecular target in cancer therapeutics. Tumour Biol.
34:2497–2506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Neuzillet C, Tijeras-Raballand A, de
Mestier L, Cros J, Faivre S and Raymond E: MEK in cancer and cancer
therapy. Pharmacol Ther. 141:160–171. 2014. View Article : Google Scholar
|
|
24
|
Schmitt JM, Abell E, Wagner A and Davare
MA: ERK activation and cell growth require CaM kinases in MCF-7
breast cancer cells. Mol Cell Biochem. 335:155–171. 2010.
View Article : Google Scholar
|
